News

Aug 2

2022

Phanes Therapeutics’ anti-CD47 antibody patent granted in the US

SAN DIEGO, Aug. 2, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in...
Read More

Jul 1

2022

Phanes Therapeutics’ PT886 granted Orphan Drug Designation for the treatment of pancreatic cancer by the FDA

SAN DIEGO, June 30, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in...
Read More

Jun 21

2022

Phanes Therapeutics’ PT217 receives Orphan Drug Designation for small cell lung cancer from the FDA

SAN DIEGO, June 21, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in...
Read More

Jun 15

2022

Phanes Therapeutics announces FDA IND clearance for PT886, an anti-claudin18.2/anti-CD47 bispecific antibody being developed for patients with gastric, gastroesophageal junction, and pancreatic cancers

SAN DIEGO, June 15, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical...
Read More

Apr 21

2022

Phanes Therapeutics revealed manufacturing validation of its bispecific technology platforms PACbody™ and SPECpair™ at AACR 2022

SAN DIEGO, April 20, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and development in immuno-oncology,...
Read More

Apr 13

2022

Phanes Therapeutics’ anti-CD73 antibody patent granted in the US

SAN DIEGO, April 12, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and development in immuno-oncology,...
Read More

Mar 23

2022

Phanes Therapeutics announces FDA IND clearance for PT199, a next generation monoclonal antibody against human CD73

SAN DIEGO, March 22, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in immuno-oncology...
Read More

Mar 17

2022

Phanes Therapeutics Announces Three Upcoming Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting

SAN DIEGO, March 16, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and development in immuno-oncology,...
Read More

Feb 8

2022

Phanes Therapeutics’ antibody patent granted

SAN DIEGO, Feb. 4, 2022 Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and development in immuno-oncology announced...
Read More

Jan 12

2022

Phanes Therapeutics announces the appointment of Vice President of Business Development

SAN DIEGO, Jan. 11, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research in immuno-oncology announced today that...
Read More